RA CAPITAL MANAGEMENT L P
Q1 2022 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001346824
· CRD 160174
· SEC-registered investment adviser
$4.6B Reported Value Total
RA CAPITAL MANAGEMENT, LP reports 9 total accounts under management (AUM). There are 9 discretionary accounts valued at $10,147,001,376, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
6 funds
· $16.3B gross asset value
Hedge Fund: $14.5B · Venture Capital Fund: $1.8B
Source: Form ADV filed 2026-03-31
Reported value
$4.6B
Quarter over quarter
-25.2%
Holdings
96
Top-10 concentration
44.8%
Key People
Form ADV owners & control persons
Richard H. (mi Only) Aldrich
PARTNER
Peter (nmn) Kolchinsky
PORTFOLIO MANAGER
Craig Alan Randall
GENERAL COUNSEL
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q1 2022 13F record
Q1 2022 13F filing summary
| Period of report | March 31, 2022 |
|---|---|
| Filed | May 16, 2022 |
| Form | 13F-HR |
| Reported value | $4.6B |
| Positions | 96 |
| Change in reported value | -19.2% |
| New positions | 10 |
| Exited positions | 11 |
| Position turnover | 19.6% |
| Top-10 concentration | 44.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
84 | $11.5B |
|
Q1 2026 13F
Filed May 15, 2026
|
85 | $9.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
71 | $9.8B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
67 | $8.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
63 | $5.9B |
|
Q1 2025 13F
Filed May 15, 2025
|
85 | $6.0B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
89 | $7.5B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
81 | $8.7B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
78 | $7.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
76 | $7.9B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
62 | $6.4B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
66 | $5.1B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
54 | $5.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
59 | $4.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
70 | $4.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
81 | $4.7B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
88 | $3.8B |
|
Q1 2022 13F
Filed May 16, 2022
|
96 | $4.6B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
97 | $5.7B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
95 | $7.2B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | $888.2M | 19.38% |
| 2 | BIIB BIOGEN INC | $153.1M | 3.34% |
| 3 | AVTE AEROVATE THERAPEUTICS INC | $151.5M | 3.31% |
| 4 | CTKB CYTEK BIOSCIENCES INC | $144.2M | 3.15% |
| 5 | ITOS ITEOS THERAPEUTICS INC | $142.1M | 3.1% |
| 6 | TVTX TRAVERE THERAPEUTICS INC | $126.9M | 2.77% |
| 7 | JANX JANUX THERAPEUTICS INC | $124.3M | 2.71% |
| 8 | PCVX VAXCYTE INC | $110.6M | 2.41% |
| 9 | ELYM ELIEM THERAPEUTICS INC | $110.3M | 2.41% |
| 10 | IMGN IMMUNOGEN INC | $103.5M | 2.26% |
| 11 | DICE DICE THERAPEUTICS INC | $99.6M | 2.17% |
| 12 | GHRS GH RESEARCH PLC | $88.3M | 1.93% |
| 13 | FMTX FORMA THERAPEUTICS HLDGS INC | $83.8M | 1.83% |
| 14 | TYRA TYRA BIOSCIENCES INC | $77.4M | 1.69% |
| 15 | PNT POINT BIOPHARMA GLOBAL INC | $71.8M | 1.57% |
| 16 | CLDX CELLDEX THERAPEUTICS INC NEW | $70.7M | 1.54% |
| 17 | BLU BELLUS HEALTH INC NEW | $70.4M | 1.54% |
| 18 | ENTA ENANTA PHARMACEUTICALS INC | $68.6M | 1.5% |
| 19 | VOR VOR BIOPHARMA INC | $67.2M | 1.47% |
| 20 | NKTX NKARTA INC | $63.8M | 1.39% |
Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.